The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis

[21] Heigener D(2018)Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Lancet Oncol 17 1497-265

[22] Hall RD(2016)Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol 20 924-1859

[23] Le TM(2019)Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 13 S332-199

[24] Haggstrom DE(2018)IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC J Thorac Oncol 343 d5928-746

[25] Gentzler RD(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 10 6261-8

[26] Garon EB(2019)Immune-checkpoint inhibitors as the first line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials J Cancer 6 155-undefined

[27] Ciuleanu T-E(2018)Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis J Immunother Cancer 359 1350-undefined

[28] Arrieta O(2018)Cancer immunotherapy using checkpoint blockade Science 8 328-undefined

[29] Reck M(2016)PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations Sci Transl Med 387 1540-undefined

[30] Kaiser R(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 389 255-undefined

[21] Heigener D(2018)Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study Lancet Oncol 17 1497-265

[22] Hall RD(2016)Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study Lancet Oncol 20 924-1859

[23] Le TM(2019)Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial Lancet Oncol 13 S332-199

[24] Haggstrom DE(2018)IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC J Thorac Oncol 343 d5928-746

[25] Gentzler RD(2011)The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials BMJ 10 6261-8

[26] Garon EB(2019)Immune-checkpoint inhibitors as the first line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials J Cancer 6 155-undefined

[27] Ciuleanu T-E(2018)Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis J Immunother Cancer 359 1350-undefined

[28] Arrieta O(2018)Cancer immunotherapy using checkpoint blockade Science 8 328-undefined

[29] Reck M(2016)PD-L1 (B7–H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations Sci Transl Med 387 1540-undefined

[30] Kaiser R(2016)Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Lancet 389 255-undefined